02186 LUYE PHARMA
- 2.970
- -0.050-1.66%
LUYE PHARMA News
Huaan Securities: Maintaining Luye Pharmaceutical's (02186) “Buy” Rating Rapid Growth in Sales Revenue in 2023
Luye Pharmaceutical (2186.HK): Sales revenue is growing rapidly, and business globalization is progressing steadily
Tianfeng Securities: Target price of HK$4.97 for the initial “buy” rating for Luye Pharmaceuticals (02186)
Luye Pharmaceutical (2186.HK): Mature products are growing steadily, new product volume is imminent, central nervous system and globalization continue to lead
Luye Pharmaceutical (02186.HK): Strong growth in product sales revenue and intensive delivery of innovative products
Luye Pharmaceutical (02186.HK) 2022 Annual Report Review: Mature Varieties Steady Recovery, Innovation Pipeline Continues to Fulfill
Luye Pharmaceutical (02186.HK): Risperidone microspheres approved by the FDA for listing in the domestic CNS field achieved zero breakthroughs overseas
Luye Pharmaceutical (02186.HK): Risperidone microspheres approved for marketing in the US, Luye Pharmaceutical opens a new chapter of growth
Daimo: Yuki Luye Pharmaceutical (02186) raised the target price for the “holdings reduction” rating to HK$2.15
Luye Pharmaceutical (02186.HK): Whether domestic or not, the dawn has come from overseas
Luye Pharmaceutical (02186.HK): Various businesses have been steadily advancing throughout the year, and the research pipeline is poised for development
Luye Pharmaceutical (02186.HK): Innovative drugs with a smooth transition in the first half of the year will soon enter a harvest period
Luye Pharmaceutical (02186.HK): New products are expected to lead to accelerated growth after short-term fluctuations in listing performance
Luye Pharmaceutical (2186.HK): Targeted Issuance to Improve Financial Structure
Luye Pharmaceutical (02186.HK): As a result of the early layout blossoming, the company entered a harvest period
Luye Pharmaceutical (2186.HK): Accelerate clinical development of abasepipp biosimilar drugs with Okanvision
Green Leaf Pharmaceutical (2186.HK): a positive catalyst related to a number of listing approvals
Luye Pharmaceutical (2186.HK): R&D steadily promotes abundant pipelines to ensure sustainable development
Green Leaf Pharmaceutical (02186.HK): affected by the epidemic in the first half of the year, performance declined compared with the same period last year, innovation and R & D continued to advance.
Green Leaf Pharmaceutical (2186.HK): clinical promotion positive / risk-return attraction worthy of market re-examination
Analysis
Price Target
No Data
